|Chemical and physical data|
|Molar mass||267.774 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Alagebrium (formerly known as ALT-711) was a drug candidate developed by Alteon, Inc. It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs), thereby reversing one of the main mechanisms of aging. Through this effect Alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking. Alagebrium has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic heart failure.
This section needs additional citations for verification. (April 2010) (Learn how and when to remove this template message)
AGEs are structures that form irreversibly when carbohydrates react non-enzymatically with proteins, lipids, or DNA. Many proteins, including structural proteins such as collagen and elastin, play an integral role in the architecture of tissues and organs and maintenance of cardiovascular elasticity and vascular wall integrity. Accumulation of these glycocedic cross-linkages can impair the normal function of organs, thicken arteries, stiffen muscles, or lead to other characteristic declines of biolological aging. In addition to this, the formation of AGE crosslinks leads to increased stiffness and loss of function of tissues and organs, and abnormal protein accumulation, which together cause many of the complications of aging and diabetes. Diabetic individuals form excessive amounts of AGEs earlier in life than non-diabetic individuals. AGEs are also known to induce oxidative stress, in which reactive molecules provoke the underlying component of inflammation.
Pharmacologic intervention with alagebrium directly targets the biochemical pathway leading to the stiffness of the cardiovascular system. Removal of the AGEs by cleavage of the abnormal crosslinking bonds has been associated with diminished inflammatory and sclerotic signaling pathways. These pathways are responsible for the deposition of abnormal amounts of matrix proteins that physically stiffen tissues. The presence of AGE crosslinks also renders tissues and organs less susceptible to normal turnover thus enhancing the presence of these abnormal bonds on various molecules. Importantly, alagebrium does not disrupt the natural carbohydrate modification to proteins, intra-molecular crosslinking or peptide bonds that are responsible for maintaining the normal integrity of the collagen chain. Thus, normal structure and function is preserved while abnormal crosslinking is reduced.
Alteon said that it had selected ALT-711 as its lead AGE-breaker based on preclinical results in its annual report for the year 1997 and that it was preparing an IND filing.
In 2006 Alteon merged with a company called HaptoGuard that had cash and a potential diagnostic test for haptoglobin; as part of the merger Genentech, which held preferred shares in Alteon, converted their shares to common ones and received the right to get milestone payments and royalties on sales of alagebrium, and option rights to license ALT-2074. In 2007, the company changed its name to Synvista Therapeutics, Inc. Synvista announced that it was terminating clinical trials of alagebrium in January 2009 in order to focus on the diagnostic test and another clinical candidate SYI-2074 (formerly ALT-2074). The company seems to have discontinued operations and their website is no longer available.
- "R&D overview: A.G.E. crosslink breakers and Alagebrium". Alteon Corporation. Archived from the original on 1 July 2007. Retrieved 4 July 2007.
- "Product Candidate: A.G.E. crosslink breakers". Alteon Corporation. Archived from the original on 1 July 2007. Retrieved 4 July 2007.
- Lisa Melton (June 2000). "AGEing – breaking the bonds" (2). Novartis Foundation Bulletin. Archived from the original on 6 August 2007. Retrieved 4 July 2007.
- Carmia Borek (August 2001). "Age breakers" (2). Life Extension Magazine. Retrieved 4 July 2007.
- Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S (2004). "Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process". American Journal of Hypertension. 17 (12 , Pt , 2): 23S–30S. doi:10.1016/j.amjhyper.2004.08.022. PMID 15607432.
- Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC (2005). "The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure". Journal of Cardiac Failure. 11 (3): 191–195. doi:10.1016/j.cardfail.2004.09.010. PMID 15812746.
- Melton, Lisa (July 2000). "AGE Breakers". Scientific American.
- Monnier VM, Sell DR (2006). "Prevention and repair of protein damage by the Maillard reaction in vivo". Rejuvenation Research. 9 (2): 264–273. doi:10.1089/rej.2006.9.264. PMID 16706654.
- "Recommended INN: List 53" (PDF). WHO Drug Information. 19 (1). 2005.
- "Alteon 10-K For the fiscal year ended December 31, 1997". Alteon via SEC Edgar. 31 March 1998.
- "Proposed INN: List 91" (PDF). WHO Drug Information. 18 (2). 2004.
- "10-K For the fiscal year ended December 31, 2007". www.sec.gov. Synvista Therapeutics via SEC Edgar. 15 March 2008.
- Myers, Calisha (29 January 2009). "Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update". FierceBiotech.